Regen BioPharma Reports Financial Results for Quarter and Nine Months Ended June 30, 2026

Regen BioPharma Inc. reported its financial results for the quarter and nine months ended June 30, 2026, revealing a net revenue of $59,065 for the quarter, consistent with the same period in 2025. For the nine-month period, the company also maintained net revenue at $177,194, reflecting no significant change year-over-year. The revenue breakdown included $31,640 from standard operations and $27,425 from related party transactions, both figures remaining unchanged from the previous year.

Operating expenses for the quarter decreased significantly to $34,536 from $99,821 in the prior year, primarily due to reduced general and administrative costs and consulting fees. The company reported a profit from operations of $24,528, a notable turnaround from the loss of $40,756 in the same quarter of 2025. However, the overall net loss for the quarter was $637,785, compared to a loss of $167,292 in the previous year, largely attributed to a substantial derivative loss of $623,200 recognized during the period.

For the nine-month period, total operating expenses surged to $857,999 from $392,680 in the prior year, driven by increased consulting and professional fees, as well as general and administrative expenses. The operating loss for this period was $680,805, compared to a loss of $215,485 in the same period of 2025. Despite these challenges, the company reported a net loss of $613,711 for the nine months, an improvement from the $702,033 loss recorded in the previous year, aided by a derivative income of $177,654.

In terms of strategic developments, Regen BioPharma has been actively engaged in the development of regenerative medical applications, focusing on small molecules that modulate immune responses for oncology and autoimmune diseases. The company has not yet received FDA approval for any of its products, and it continues to seek additional funding through equity or debt offerings to support its operations and development plans. As of June 30, 2026, the company had cash reserves of $239 and an accumulated deficit of approximately $22 million, raising concerns about its ability to continue as a going concern without further financing.

Looking ahead, Regen BioPharma's management has expressed the need for additional working capital to sustain its operations and execute its business strategy. The company is exploring various avenues for funding, but it acknowledges the uncertainty surrounding its ability to secure necessary financing. The financial statements reflect a substantial doubt regarding the company's ability to continue operations over the next twelve months without additional capital.